Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial (Lancet Infectious Diseases, 2020)

(untitled) - Folegatti, PM; Bittaye, M; Flaxman, A; Ramos Lopez, F; Bellamy, D; Mair, C; Makinson, R; Sheridan, J; Boyd, A; Tran, N; Silman, D; Poulton, I; et al.